Chart of the Week: Hepatitis C - Gilead Wins

In honor of Gilead's newly approved, and cheaper, hepatitis C drug we decided to show the biomarker, trial and company landscape for hepatitis C. You can read more about Gilead's new drug here, here and here.

LDT Companies Out-Perform IVD Companies

Last week we posted an analysis of the growth rates and market caps for companies that develop IVD tests (which was in itself a follow-up to some analyses from a couple of years ago).  This week we are presenting the same analysis for developers of lab-developed tests (LDTs).  On both of the ...

Chart of the Week: Value Network of Healthcare

We are mildly obssessed with our customers and the markets into which we sell BiomarkerBase™.  We have been thinking lately about the value chain in healthcare and have concluded that, like most industries, it's quite complicated.  We have tried to represent the "value network" of healthcare below. ...

Dx Test Developers Experience Declining Revenue Growth

The news this week that CMS may reduce rates for some molecular diagnostic tests (by over 70% in a couple of cases) stimulated the idea of taking a quick look at the current market dynamics for diagnostic test developers.

Chart of the Week: Panels Emerging, Single Biomarker Tests Dominate

For the chart of the week we wanted to explore the market for multi-analyte panels.  We found that single biomarker tests still vastly outnumber panels.  Stay tuned for more trending information in the coming weeks.  My hypothesis: Panels, even outside of NGS, are being introduced to the market ...

Chart of the Week: Biopharma Players in Alzheimers

We've published a few "graphs" illustrating topics interesting to us.  Last month published a graph showing Celgene's biomarker and trial activities.  More recently we published a biomarker and trial landscape graph for Alzheimer's disease. Because Alzheimer's is getting a lot of attention at the ...




Pharmacovigilance and Safety Biomarkers

New Call-to-action

Subscribe for Updates

Download our Free IVD Trends Report